nefrНефрологияNephrology (Saint-Petersburg)1561-62742541-9439Pavlov First Saint-Petersburg State Medical Universitynefr-163Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESГемолитико-уремический синдром, ассоциированный с шига-токсин-продуцирующей Esherichia соїіHemolytic uremic syndrome associated with shiga-toxin-producing Esherichia coliЭмироваХадижа МартовнаEmirovaKhadizhakh.emirova@outlook.comТолстоваЕвгения МихайловнаTolstovaEvgeniya M.tepec@yandex.ruКаганМихаил ЮдовичKaganOlga M.mkaganorenburg@yahoo.comОрловаОльга МихайловнаOrlovaMikhail Yu.olmigor@yandex.ruАбасееваТатьяна ЮрьевнаAbaseevaTatianatatyanaab@mail.ruПанкратенкоТатьяна ЕвгеньевнаPancratenkoTatiana E.tatiana2103@inbox.ruШпикаловаИрина ЮрьевнаShpikalovaIrina Yu.ikucherova@yandex.ruМосковский государственный медико-стоматологический университет им. А.И. ЕвдокимоваРоссияMoscow State University of Medicine and Dentistry named after A.I.EvdokimovRussian FederationОбластная детская клиническая больницаРоссияOrenburg Regional Children’s HospitalRussian FederationМосковский областной научно-исследовательский клинический институт им. М.Ф. ВладимирскогоРоссияMoscow Regional Scientific Research Clinical Institute named after M.F.VladimirskiyRussian FederationДетская городская клиническая больница святого ВладимираРоссияSt. Vladimir's Clinical Children HospitalRussian Federation2016010320162021832Copyright © Эмирова Х.М., Толстова Е.М., Каган М.Ю., Орлова О.М., Абасеева Т.Ю., Панкратенко Т.Е., Шпикалова И.Ю., 20162016Эмирова Х.М., Толстова Е.М., Каган М.Ю., Орлова О.М., Абасеева Т.Ю., Панкратенко Т.Е., Шпикалова И.Ю.Emirova K., Tolstova E.M., Kagan O.M., Orlova M.Y., Abaseeva T., Pancratenko T.E., Shpikalova I.Y.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephrolog.ru/jour/article/view/163

Значительный прогресс в понимании природы этого заболевания в последнее десятилетие позволяет говорить о гемолитико-уремическом синдроме как о гетерогенной группе заболеваний, относящихся к одному классу тромботических микроангиопатий, характеризующихся различной этиологией и патогенезом. Представленный обзор посвящен наиболее распространенной форме гемолитико-уремическом синдрома, ассоциированного с шига- токсин-продуцирующей E.coli (STEC-ГУС). Обобщены последние данные, касающиеся этиологии, патогенеза и терапии типичного гемолитико-уремического синдрома с акцентом на механизмы реализации патологического процесса и новые подходы к терапии.

Based on significant progress in understanding the disease pathogenesis in the past decade hemolytic-uremic syndrome is appear to be heterogeneous group of diseases from the class of thrombotic microangiopathy with different etiology and pathogenesis. This review is dedicated to the most common form of hemolytic-uremic syndrome associated with Shiga toxin-producing E.coli (STEC-HUS). We summarized the latest data about etiology, pathogenesis and therapy of typical hemolytic-uremic syndrome with a focus on the mechanisms of the pathological process and new therapy approaches.

гемолитико-уремический синдромтромботическая микроангиопатияшига-токсингемолитическая анемиятромбоцитопенияострое повреждение почекhemolytic uremic syndromethrombotic microangiopathyShiga toxinhemolytic anemiathrombocytopeniaacute kidney injuryReferencesKarmali M.A., Petric M., Lim C. et al. Escherichia coli cytotoxin., haemolytic-uraemic syndrome., and haemorrhagic colitis. Lancet. 1983; 3;2(8362):1299-1300Karmali M.A., Petric M., Lim C. et al. Escherichia coli cytotoxin., haemolytic-uraemic syndrome., and haemorrhagic colitis. Lancet. 1983; 3;2(8362):1299-1300Noris M., Mescia F., Remuzzi G. STEC-HUS., atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol. 2012; 8(11): 622-633Noris M., Mescia F., Remuzzi G. STEC-HUS., atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol. 2012; 8(11): 622-633Scheiring J., Andreoli Sh.P., Zimmerhackl L.B. Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS) Pediatr Nephrol. 2008; 23: 1749-1760Scheiring J., Andreoli Sh.P., Zimmerhackl L.B. Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS) Pediatr Nephrol. 2008; 23: 1749-1760Johnson S., Taylor C.M. What’s new in hemolytic uremic syndrome. Eur J Pediatr. 2008. 167: 965-971Johnson S., Taylor C.M. What’s new in hemolytic uremic syndrome. Eur J Pediatr. 2008. 167: 965-971Besbas N., Karpman D., Landau D. et al. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney International. 2006. 70: 423-431Besbas N., Karpman D., Landau D. et al. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney International. 2006. 70: 423-431Loirat C., Fakhouri F., Ariceta G. et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016;31(1):15-39Loirat C., Fakhouri F., Ariceta G. et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016;31(1):15-39Constantinescu A.R., Bitzan M., Weiss L.S. et al. Non-entero-pathic hemolytic uremic syndrome: causes and short-term course. Am J Kidney Dis. 2004; 43: 976-982Constantinescu A.R., Bitzan M., Weiss L.S. et al. Non-entero-pathic hemolytic uremic syndrome: causes and short-term course. Am J Kidney Dis. 2004; 43: 976-982Sonntag A.K., Prager R. et al. Phenotypic and genotypic analyses of enterohemorrhagic Escherichia coli O145 strains from patients in Germany. J Clin Microbiol. 2004; 42: 954-962Sonntag A.K., Prager R. et al. Phenotypic and genotypic analyses of enterohemorrhagic Escherichia coli O145 strains from patients in Germany. J Clin Microbiol. 2004; 42: 954-962Ruggenenti P., Noris М., Remuzzi G. Thrombotic microangiopathy., hemolytic uremic syndrome., and thrombotic thrombocytopenic purpura. Kidney International. 2001. 60: 831-846Ruggenenti P., Noris М., Remuzzi G. Thrombotic microangiopathy., hemolytic uremic syndrome., and thrombotic thrombocytopenic purpura. Kidney International. 2001. 60: 831-846Loirat C., Taylor C.M. Hemolytic Uremic Syndromes. In: Pediatric Nephrology., 4th ed., Avner E.D., Harmon W.E., Niaudet P. (Eds)., Lippincott., Williams & Wilkins., Baltimore 2004:887Loirat C., Taylor C.M. Hemolytic Uremic Syndromes. In: Pediatric Nephrology., 4th ed., Avner E.D., Harmon W.E., Niaudet P. (Eds)., Lippincott., Williams & Wilkins., Baltimore 2004:887Lynn R.M., O’Brien S.J., Taylor C.M. et al. Childhood hemolytic uremic syndrome United Kingdom and Ireland Emerg Infect Dis. 2005; 11: 590-596Lynn R.M., O’Brien S.J., Taylor C.M. et al. Childhood hemolytic uremic syndrome United Kingdom and Ireland Emerg Infect Dis. 2005; 11: 590-596Tarr P.I., Gordon C.A., Chandler W.L. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet. 2005;365:1073-1086Tarr P.I., Gordon C.A., Chandler W.L. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet. 2005;365:1073-1086Molbak K., Mead P.S., Griffin P.M. Antimicrobial therapy in patients with Escherichia coli O157:H7 infection. JAMA. 2002; 288(8):1014-1016Molbak K., Mead P.S., Griffin P.M. Antimicrobial therapy in patients with Escherichia coli O157:H7 infection. JAMA. 2002; 288(8):1014-1016Gerber A., Karch H. et al. Clinical Course and the Role of Shiga Toxin Producing Escherichia coli infection in the haemolytic uraemic syndrome in pediatric patients., 1997-2000 in Germany and Austria: a prospective study. J Infect Dis. 2002; 186:493-500Gerber A., Karch H. et al. Clinical Course and the Role of Shiga Toxin Producing Escherichia coli infection in the haemolytic uraemic syndrome in pediatric patients., 1997-2000 in Germany and Austria: a prospective study. J Infect Dis. 2002; 186:493-500Bielaszewska M., Kock R., Friedrich A.W. Shiga Toxin-Mediated Hemolytic Uremic Syndrome: Time to Change the Diagnostic Paradigm? PLoS ONE. 2007. 10. e1024Bielaszewska M., Kock R., Friedrich A.W. Shiga Toxin-Mediated Hemolytic Uremic Syndrome: Time to Change the Diagnostic Paradigm? PLoS ONE. 2007. 10. e1024Mellmann A., Bielaszewska M. et al. Enterohemorrhagic Escherichia coli in human infection: in vivo evolution of a bacterial pathogen. Clin Infect Dis. 2005; 41:785-792Mellmann A., Bielaszewska M. et al. Enterohemorrhagic Escherichia coli in human infection: in vivo evolution of a bacterial pathogen. Clin Infect Dis. 2005; 41:785-792Zimmerhackl L.B., Rosales A. et al. Enterohemorrhagic Escherichia coli O26:H11-Associated Hemolytic Uremic Syndrome: Bacteriology and Clinical Presentation. Semin Thromb Hemost. 2010; 36(6): 586-593Zimmerhackl L.B., Rosales A. et al. Enterohemorrhagic Escherichia coli O26:H11-Associated Hemolytic Uremic Syndrome: Bacteriology and Clinical Presentation. Semin Thromb Hemost. 2010; 36(6): 586-593Zhang W., Mellmann A. et al. Structural and functional differences between disease-associated genes of enterohaemorrhagic Escherichia coli O111. Int J Med Microbiol. 2007; 297: 17-26Zhang W., Mellmann A. et al. Structural and functional differences between disease-associated genes of enterohaemorrhagic Escherichia coli O111. Int J Med Microbiol. 2007; 297: 17-26Vaillant V., Espié E., de Valk H et al. Undercooked ground beef and person-to-person transmission as major risk factors for sporadic hemolytic uremic syndrome related to Shiga-toxin producing Escherchia coli infections in children in France. Pediatr Infect Dis J 2009; 28:650Vaillant V., Espié E., de Valk H et al. Undercooked ground beef and person-to-person transmission as major risk factors for sporadic hemolytic uremic syndrome related to Shiga-toxin producing Escherchia coli infections in children in France. Pediatr Infect Dis J 2009; 28:650Friedrich Alexander W., Zhang W., Bielaszewska M et al. Prevalence., virulence profiles., and clinical significance of Shiga toxin negative variants of enterohemorrhagic Escherichia coli O157 Infection in Humans. Clinical Infectious Diseases 2007; 45:39-45Friedrich Alexander W., Zhang W., Bielaszewska M et al. Prevalence., virulence profiles., and clinical significance of Shiga toxin negative variants of enterohemorrhagic Escherichia coli O157 Infection in Humans. Clinical Infectious Diseases 2007; 45:39-45Butler T. Haemolytic uraemic syndrome during shigellosis. Trans R Soc Trop Med Hyg. 2012; 106(7):395-399Butler T. Haemolytic uraemic syndrome during shigellosis. Trans R Soc Trop Med Hyg. 2012; 106(7):395-399Taylor С.М. Enterohaemorrhagic Escherichia coli and Shigella dysenteriae type 1-induced haemolytic uraemic syndrome. Pediatr Nephrol. 2008; 23:1425-1431Taylor С.М. Enterohaemorrhagic Escherichia coli and Shigella dysenteriae type 1-induced haemolytic uraemic syndrome. Pediatr Nephrol. 2008; 23:1425-1431Mbonu C.C., Davison D.L., El-Jazzar K.M. et al. Clostridium difficile colitis associated with hemolytic-uremic syndrome. Am J Kidney Dis. 2003; 41(5):14Mbonu C.C., Davison D.L., El-Jazzar K.M. et al. Clostridium difficile colitis associated with hemolytic-uremic syndrome. Am J Kidney Dis. 2003; 41(5):14Ruggenenti P., Remuzzi G.E. coli O104:H4 German outbreak: a missed opportunity» Piero Ruggenenti and Giuseppe Remuzzi. Nat. Rev. Nephrol. 2012. 8., 558-560Ruggenenti P., Remuzzi G.E. coli O104:H4 German outbreak: a missed opportunity» Piero Ruggenenti and Giuseppe Remuzzi. Nat. Rev. Nephrol. 2012. 8., 558-560Scheutz F. et al. Characteristics of the enteroaggregative Shiga toxin/verotoxin-producing Escherichia coli O104:H4 strain causing the outbreak of haemolytic uraemic syndrome in Germany., May to June 2011. Euro. Surveill. 2011; 16:198-89Scheutz F. et al. Characteristics of the enteroaggregative Shiga toxin/verotoxin-producing Escherichia coli O104:H4 strain causing the outbreak of haemolytic uraemic syndrome in Germany., May to June 2011. Euro. Surveill. 2011; 16:198-89Dundas S. et al. The central Scotland Escherichia coli O157:H7 outbreak: risk factors for the hemolytic uremic syndrome and death among hospitalized patients. Clin. Infect. Dis. 2001; 33: 923-931Dundas S. et al. The central Scotland Escherichia coli O157:H7 outbreak: risk factors for the hemolytic uremic syndrome and death among hospitalized patients. Clin. Infect. Dis. 2001; 33: 923-931Fukushima H. et al. Clinical experiences in Sakai City Hospital during the massive outbreak of enterohemorrhagic Escherichia coli O157 infections in Sakai City., 1996. Pediatr. Int. 1999;41: 213-217Fukushima H. et al. Clinical experiences in Sakai City Hospital during the massive outbreak of enterohemorrhagic Escherichia coli O157 infections in Sakai City., 1996. Pediatr. Int. 1999;41: 213-217Trofa A.F., Ueno-Olsen H., Oiwa R., Yoshikawa M. Dr. Kiyoshi Shiga: discoverer of the dysentery bacillus. Clin Infect Dis. 1999. 29:1303-1306Trofa A.F., Ueno-Olsen H., Oiwa R., Yoshikawa M. Dr. Kiyoshi Shiga: discoverer of the dysentery bacillus. Clin Infect Dis. 1999. 29:1303-1306Conradi H. Uber Iosliche., durch asptische Autolyse erhaltene Giftstoffe vonRuhr- und Typhus-Bazillen. Dtsch Med Wochenschr 1903; 29:26-28Conradi H. Uber Iosliche., durch asptische Autolyse erhaltene Giftstoffe vonRuhr- und Typhus-Bazillen. Dtsch Med Wochenschr 1903; 29:26-28Bridgwater F.A., Morgan R.S., Rowson K.E., Wright G.P. The neurotoxin of Shigella shigae: morphological and functional lesions produced in the central nervous system of rabbits. Br J Exp Pathol. 1955; 36(5):447-453Bridgwater F.A., Morgan R.S., Rowson K.E., Wright G.P. The neurotoxin of Shigella shigae: morphological and functional lesions produced in the central nervous system of rabbits. Br J Exp Pathol. 1955; 36(5):447-453Konowalchuk J., Speirs J.I., Stavric S. Vero response to a cytotoxin of Escherichia coli. Infect Immun. 1977;18(3):775-779Konowalchuk J., Speirs J.I., Stavric S. Vero response to a cytotoxin of Escherichia coli. Infect Immun. 1977;18(3):775-779Konowalchuk J., Dickie N., Stavric S., Speirs J.I. Properties of an Escherichia coli cytotoxin. Infect Immun. 1978 May;20(2):575-577Konowalchuk J., Dickie N., Stavric S., Speirs J.I. Properties of an Escherichia coli cytotoxin. Infect Immun. 1978 May;20(2):575-577van Setten P.A., Monnens L.A., Verstraten R.G. et al. Effects of verocytotoxin-1 on nonadherent human monocytes: binding characteristics., protein synthesis., and induction of cytokine release. Blood. 1996;88:174-183van Setten P.A., Monnens L.A., Verstraten R.G. et al. Effects of verocytotoxin-1 on nonadherent human monocytes: binding characteristics., protein synthesis., and induction of cytokine release. Blood. 1996;88:174-183O’Brien A.D., LaVeck G.D. Purification and characterization of a Shigella dysenteriae 1-like toxin produced by Escherichia coli. Infect Immun. 1983; 40:675-683O’Brien A.D., LaVeck G.D. Purification and characterization of a Shigella dysenteriae 1-like toxin produced by Escherichia coli. Infect Immun. 1983; 40:675-683O’Brien A.O., Lively T.A., Chen M.E. et al. Escherichia coli O157:H7 strains associated with haemorrhagic colitis in the United States produce a Shigella dysenteriae 1 (SHIGA) like cytotoxin. Lancet. 1983; 26 (1):702O’Brien A.O., Lively T.A., Chen M.E. et al. Escherichia coli O157:H7 strains associated with haemorrhagic colitis in the United States produce a Shigella dysenteriae 1 (SHIGA) like cytotoxin. Lancet. 1983; 26 (1):702Scheutz F., Teel L.D., Beutin L et al. Multicenter evaluation of a sequence-based protocol for subtyping Shiga toxins and standardizing Stx nomenclature. J Clin Microbiol 2012. 50:2951-2963Scheutz F., Teel L.D., Beutin L et al. Multicenter evaluation of a sequence-based protocol for subtyping Shiga toxins and standardizing Stx nomenclature. J Clin Microbiol 2012. 50:2951-2963Eklund M., Leino K., Siitonen A. Clinical Escherichia coli strains carrying stx genes: stx variants and stx-positive virulence profiles. J Clin Microbiol. 2002; 40(12):4585-4593Eklund M., Leino K., Siitonen A. Clinical Escherichia coli strains carrying stx genes: stx variants and stx-positive virulence profiles. J Clin Microbiol. 2002; 40(12):4585-4593Persson S1., Olsen K.E., Ethelberg S., Scheutz F. Subtyping method for Escherichia coli shiga toxin (verocytotoxin) 2 variants and correlations to clinical manifestations. J Clin Microbiol. 2007;45(6):2020-2024Persson S1., Olsen K.E., Ethelberg S., Scheutz F. Subtyping method for Escherichia coli shiga toxin (verocytotoxin) 2 variants and correlations to clinical manifestations. J Clin Microbiol. 2007;45(6):2020-2024Fraser M.E., Cherney M.M., Marcato P. et al. Binding of adenine to Stx2., the protein toxin from Escherichia coli O157:H7. Acta Crystallogr Sect F Struct Biol Cryst Commun 2006; 62:627-630Fraser M.E., Cherney M.M., Marcato P. et al. Binding of adenine to Stx2., the protein toxin from Escherichia coli O157:H7. Acta Crystallogr Sect F Struct Biol Cryst Commun 2006; 62:627-630Bertin Y., Boukhors K., Pradel N. et al. Stx2 subtyping of Shiga toxin-producing Escherichia coli isolated from cattle in France: detection of a new Stx2 subtype and correlation with additional virulence factors. J Clin Microbiol. 2001: 3060-3065Bertin Y., Boukhors K., Pradel N. et al. Stx2 subtyping of Shiga toxin-producing Escherichia coli isolated from cattle in France: detection of a new Stx2 subtype and correlation with additional virulence factors. J Clin Microbiol. 2001: 3060-3065Beutin L., Miko A., Krause G et al. Identification of human-pathogenic strains of Shiga toxin-producing Escherichia coli from food by combination of serotyping and molecular typing of Shiga toxin genes. Appl Environ Microbiol. 2007. 73: 4769-4775Beutin L., Miko A., Krause G et al. Identification of human-pathogenic strains of Shiga toxin-producing Escherichia coli from food by combination of serotyping and molecular typing of Shiga toxin genes. Appl Environ Microbiol. 2007. 73: 4769-4775Brett K.N., Ramachandram V., Hornitzky M.A. et al. Stx1c is the most common Shiga toxin 1 subtype among in Shiga toxin producing Escherichia coli 491 isolates from sheep but not among isolates from cattle. J Clin Microbiol. 2003; 41: 926-936Brett K.N., Ramachandram V., Hornitzky M.A. et al. Stx1c is the most common Shiga toxin 1 subtype among in Shiga toxin producing Escherichia coli 491 isolates from sheep but not among isolates from cattle. J Clin Microbiol. 2003; 41: 926-936Gobius K.S., Higgs G.M., Desmarchelier P.M. Presence of activatable Shiga toxin genotype (stx2d) in Shiga toxigenic Escherichia coli from livestock sources. J Clin Microbiol. 2003; 41:3777-3783Gobius K.S., Higgs G.M., Desmarchelier P.M. Presence of activatable Shiga toxin genotype (stx2d) in Shiga toxigenic Escherichia coli from livestock sources. J Clin Microbiol. 2003; 41:3777-3783Krüger A., Lucchesi P.A. Verotoxins in bovine and meat verotoxin-producing Escherichia coli isolates: type., number of variants., and relationship to cytotoxicity. Appl Environ Microbiol. 2011; 77:73-79Krüger A., Lucchesi P.A. Verotoxins in bovine and meat verotoxin-producing Escherichia coli isolates: type., number of variants., and relationship to cytotoxicity. Appl Environ Microbiol. 2011; 77:73-79Linggood M.A., Thompson J.M. Verotoxin production among porcine strains of Escherichia coli and its association with edema disease. J Med Microbiol. 1987; 25: 359-362Linggood M.A., Thompson J.M. Verotoxin production among porcine strains of Escherichia coli and its association with edema disease. J Med Microbiol. 1987; 25: 359-362Schmidt H., Scheef J., Morabito S. et al. A new shiga toxin 2 variant (Stx2f) from Escherichia coli isolated from pigeons. Appl. Environ Microbiol. 2000; 66., 1205-1208Schmidt H., Scheef J., Morabito S. et al. A new shiga toxin 2 variant (Stx2f) from Escherichia coli isolated from pigeons. Appl. Environ Microbiol. 2000; 66., 1205-1208Friesema I., van der Zwaluw K., Schuurman T. et al. Emergence of Escherichia coli encoding Shiga toxin 2f in human Shiga toxin- producing E. coli (STEC) infections in the Netherlands., January 2008 to December 2011. Euro Surveill. 2014; 19 (17): 26-32Friesema I., van der Zwaluw K., Schuurman T. et al. Emergence of Escherichia coli encoding Shiga toxin 2f in human Shiga toxin- producing E. coli (STEC) infections in the Netherlands., January 2008 to December 2011. Euro Surveill. 2014; 19 (17): 26-32Shimizu H., Field R.A., Homans S.W., Donohue-Rolfe A. Solution structure of the complex between the B-subunit homopentamer of verotoxin VT-1 from Escherichia coli and the trisaccharide moiety of globotriaosylceramide. Biochemistry. 1998;37: 11078-11082Shimizu H., Field R.A., Homans S.W., Donohue-Rolfe A. Solution structure of the complex between the B-subunit homopentamer of verotoxin VT-1 from Escherichia coli and the trisaccharide moiety of globotriaosylceramide. Biochemistry. 1998;37: 11078-11082Ling H., Boodhoo A., Hazes B. et al. Structure of the Shiga-like toxin I B-pentamer complexed with an analogue of its receptor Gb3. Biochemistry. 1998;37:1777-1788Ling H., Boodhoo A., Hazes B. et al. Structure of the Shiga-like toxin I B-pentamer complexed with an analogue of its receptor Gb3. Biochemistry. 1998;37:1777-1788Sandvig K., Garred O., Prydz K. et al. Retrograde transport of endocytosed Shiga toxin to the endoplasmic reticulum. Nature. 1992; 6;358(6386):510-512Sandvig K., Garred O., Prydz K. et al. Retrograde transport of endocytosed Shiga toxin to the endoplasmic reticulum. Nature. 1992; 6;358(6386):510-512Endo Y., Tsurugi K., Yutsudo T. et al. Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. Eur J Biochem. 1988; 15;171(1-2):45-50Endo Y., Tsurugi K., Yutsudo T. et al. Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. Eur J Biochem. 1988; 15;171(1-2):45-50Fraser M.E., Cherney M.M., Marcato P. et al. Binding of adenine to Stx2., the protein toxin from Escherichia coli O157:H7. Acta Crystallogr Sect F Struct Biol Cryst Commun 2006; 62:627-630Fraser M.E., Cherney M.M., Marcato P. et al. Binding of adenine to Stx2., the protein toxin from Escherichia coli O157:H7. Acta Crystallogr Sect F Struct Biol Cryst Commun 2006; 62:627-630Bielaszewska M., Karch H. Consequences of enterohaemorrhagic Escherichia coli infection for the vascular endothelium. Thromb Haemost. 2005;94:312-318Bielaszewska M., Karch H. Consequences of enterohaemorrhagic Escherichia coli infection for the vascular endothelium. Thromb Haemost. 2005;94:312-318Muthing J., Schweppe C.H., Karch H., Friedrich A.W. Shiga toxins., glycosphingolipid diversity., and endothelial cell injury. Thromb Haemost. 2009;101:252-264Muthing J., Schweppe C.H., Karch H., Friedrich A.W. Shiga toxins., glycosphingolipid diversity., and endothelial cell injury. Thromb Haemost. 2009;101:252-264Richardson S.E., Karmali M.A., Becker L.E., Smith C.R. The histopathology of the hemolytic uremic syndrome associated with verocytotoxin-producing Escherichia coli infections. Hum Pathol. 1988;19:1102-1108Richardson S.E., Karmali M.A., Becker L.E., Smith C.R. The histopathology of the hemolytic uremic syndrome associated with verocytotoxin-producing Escherichia coli infections. Hum Pathol. 1988;19:1102-1108Bitzan M., Richardson S., Huang C. et al. Evidence that verotoxins (Shiga-like toxins) from Escherichia coli bind to P blood group antigens of human erythrocytes in vitro. Infect Immun. 1994;62:3337-3347Bitzan M., Richardson S., Huang C. et al. Evidence that verotoxins (Shiga-like toxins) from Escherichia coli bind to P blood group antigens of human erythrocytes in vitro. Infect Immun. 1994;62:3337-3347Cooling L.L., Walker K.E., Gille T., Koerner T.A. Shiga toxin binds human platelets via globotriaosylceramide (Pk antigen) and a novel platelet glycosphingolipid. Infect Immun. 1998;66:4355-4366Cooling L.L., Walker K.E., Gille T., Koerner T.A. Shiga toxin binds human platelets via globotriaosylceramide (Pk antigen) and a novel platelet glycosphingolipid. Infect Immun. 1998;66:4355-4366Ghosh S.A., Polanowska-Grabowska R.K., Fujii J. et al. Shiga toxin binds to activated platelets. J Thromb Haemost. 2004;2:499-506Ghosh S.A., Polanowska-Grabowska R.K., Fujii J. et al. Shiga toxin binds to activated platelets. J Thromb Haemost. 2004;2:499-506Karpman D., Papadopoulou D., Nilsson K. et al. Platelet activation by Shiga toxin and circulatory factors as a pathogenetic mechanism in the hemolytic uremic syndrome. Blood. 2001;97:3100-3108Karpman D., Papadopoulou D., Nilsson K. et al. Platelet activation by Shiga toxin and circulatory factors as a pathogenetic mechanism in the hemolytic uremic syndrome. Blood. 2001;97:3100-3108Te Loo D.M., Monnens L.A., van Der Velden T.J. et al. Binding and transfer of verocytotoxin by polymorphonuclear leukocytes in hemolytic uremic syndrome. Blood. 2000;95:3396-3402Te Loo D.M., Monnens L.A., van Der Velden T.J. et al. Binding and transfer of verocytotoxin by polymorphonuclear leukocytes in hemolytic uremic syndrome. Blood. 2000;95:3396-3402Te Loo D.M., van Hinsbergh V.W., van den Heuvel L.P., Monnens L.A. Detection of verocytotoxin bound to circulating polymorphonuclear leukocytes of patients with hemolytic uremic syndrome. J Am Soc Nephrol. 2001;12:800-806Te Loo D.M., van Hinsbergh V.W., van den Heuvel L.P., Monnens L.A. Detection of verocytotoxin bound to circulating polymorphonuclear leukocytes of patients with hemolytic uremic syndrome. J Am Soc Nephrol. 2001;12:800-806Louise C.B., Obrig T.G. Shiga toxin-associated hemolytic-uremic syndrome: combined cytotoxic effects of Shiga toxin., interleukin-1 beta., and tumor necrosis factor alpha on human vascular endothelial cells in vitro. Infect Immun. 1991;59:4173-4179Louise C.B., Obrig T.G. Shiga toxin-associated hemolytic-uremic syndrome: combined cytotoxic effects of Shiga toxin., interleukin-1 beta., and tumor necrosis factor alpha on human vascular endothelial cells in vitro. Infect Immun. 1991;59:4173-4179van de Kar N.C., Monnens L.A., Karmali M.A., van Hinsbergh V.W. Tumor necrosis factor and interleukin-1 induce expression of the verocytotoxin receptor globotriaosylceramide on human endothelial cells: implications for the pathogenesis of the hemolytic uremic syndrome. Blood. 1992;80:2755-2764van de Kar N.C., Monnens L.A., Karmali M.A., van Hinsbergh V.W. Tumor necrosis factor and interleukin-1 induce expression of the verocytotoxin receptor globotriaosylceramide on human endothelial cells: implications for the pathogenesis of the hemolytic uremic syndrome. Blood. 1992;80:2755-2764Stahl AL., Sartz L., Nelsson A. et al. Shiga toxin and lipopoly-saccharide induce platelet-leukocyte aggregates and tissue factor release., a thrombotic mechanism in hemolytic uremic syndrome. PLoS One. 2009;4:e6990Stahl AL., Sartz L., Nelsson A. et al. Shiga toxin and lipopoly-saccharide induce platelet-leukocyte aggregates and tissue factor release., a thrombotic mechanism in hemolytic uremic syndrome. PLoS One. 2009;4:e6990Iordanov M.S., Pribnow D., Magun J.L. et al. Ribotoxic stress response: activation of the stress-activated protein kinase JNK1 by inhibitors of the peptidyl transferase reaction and by sequence-specific RNA damage to the alpha-sarcin/ricin loop in the 28S rRNA. Mol Cell Biol. 1997;17:3373-3381Iordanov M.S., Pribnow D., Magun J.L. et al. Ribotoxic stress response: activation of the stress-activated protein kinase JNK1 by inhibitors of the peptidyl transferase reaction and by sequence-specific RNA damage to the alpha-sarcin/ricin loop in the 28S rRNA. Mol Cell Biol. 1997;17:3373-3381Tesh V.L. Activation of cell stress response pathways by Shiga toxins. Cell Microbiol. 2012;14:1-9Tesh V.L. Activation of cell stress response pathways by Shiga toxins. Cell Microbiol. 2012;14:1-9Tesh V.L. Induction of apoptosis by Shiga toxins. Future Microbiol. 2010.5., 431-453Tesh V.L. Induction of apoptosis by Shiga toxins. Future Microbiol. 2010.5., 431-453Zoja C., Buelli S., Morigi M. Shiga toxin-associated hemolytic uremic syndrome: pathophysiology of endothelial dysfunction. Pediatr Nephrol. 2010; 25(11):2231-2240Zoja C., Buelli S., Morigi M. Shiga toxin-associated hemolytic uremic syndrome: pathophysiology of endothelial dysfunction. Pediatr Nephrol. 2010; 25(11):2231-2240Thurman J.M., Marians R., Emlen W. et al. Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2009;4(12):1920-1924Thurman J.M., Marians R., Emlen W. et al. Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2009;4(12):1920-1924Morigi M., Galbusera M., Gastoldi S et al. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J Immunol. 2011;187:172-180Morigi M., Galbusera M., Gastoldi S et al. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J Immunol. 2011;187:172-180Orth D., Khan A.B., Naim A. et al. Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome. J Immunol 2009; 182:6394Orth D., Khan A.B., Naim A. et al. Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome. J Immunol 2009; 182:6394Ehrlenbach S., Rosales A. et al. Shiga Toxin 2 Reduces Complement Inhibitor CD59 Expression on Human Renal Tubular Epithelial and Glomerular Endothelial Cells. Infection and Immunity. 2013; 81(8): 2678-2680Ehrlenbach S., Rosales A. et al. Shiga Toxin 2 Reduces Complement Inhibitor CD59 Expression on Human Renal Tubular Epithelial and Glomerular Endothelial Cells. Infection and Immunity. 2013; 81(8): 2678-2680Arvidsson I., Stâhl A.L. et al. Shiga toxin-induced complement-mediated hemolysis and release of complement-coated red blood cell-derived microvesicles in hemolytic uremic syndrome. J Immunol. 2015; 1., 194(5): 2309-2318Arvidsson I., Stâhl A.L. et al. Shiga toxin-induced complement-mediated hemolysis and release of complement-coated red blood cell-derived microvesicles in hemolytic uremic syndrome. J Immunol. 2015; 1., 194(5): 2309-2318Stahl A.L., Sartz L., Karpman D. Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Blood. 2011;117:5503-5513Stahl A.L., Sartz L., Karpman D. Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Blood. 2011;117:5503-5513Locatelli M., Buelli S., Pezzotta A. et al. Shiga Toxin Promotes Podocyte Injury in Experimental Hemolytic Uremic Syndrome via Activation of the Alternative Pathway of Complement. Journal of the American Society of Nephrology : JASN. 2014;25(8):1786-1798Locatelli M., Buelli S., Pezzotta A. et al. Shiga Toxin Promotes Podocyte Injury in Experimental Hemolytic Uremic Syndrome via Activation of the Alternative Pathway of Complement. Journal of the American Society of Nephrology : JASN. 2014;25(8):1786-1798Wong C.S., Jelacic S., Habeeb R.L. et al. The risk of haemolytic uraemic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Eng J Med. 2000; 342:1930-1936Wong C.S., Jelacic S., Habeeb R.L. et al. The risk of haemolytic uraemic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Eng J Med. 2000; 342:1930-1936Niaudet Р. Clinical manifestations and diagnosis of Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome (HUS) in children., Up To Date., 2015Niaudet Р. Clinical manifestations and diagnosis of Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome (HUS) in children., Up To Date., 2015Caillaud C., Zaloszyc A. et al. CFH gene mutation in a case of Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS). Pediatr Nephrol. 2016; 23;31(1):157-161Caillaud C., Zaloszyc A. et al. CFH gene mutation in a case of Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS). Pediatr Nephrol. 2016; 23;31(1):157-161Fang C.J., Fremeaux-Bacchi V., Liszewski M.K. et al. Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS)., fatal Stx-HUS., C3 glomerulonephritis., and the HELLP syndrome. Blood 2008;111:624-632Fang C.J., Fremeaux-Bacchi V., Liszewski M.K. et al. Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS)., fatal Stx-HUS., C3 glomerulonephritis., and the HELLP syndrome. Blood 2008;111:624-632Paton J.C., Paton A.W. Pathogenesis and diagnosis of shiga toxin-producing Escherichia coli infections. Clin Microbiol Rev. 1998; 11:450-479Paton J.C., Paton A.W. Pathogenesis and diagnosis of shiga toxin-producing Escherichia coli infections. Clin Microbiol Rev. 1998; 11:450-479Taranta А., Gianviti А. Genetic risk factors in typical haemolytic uraemic syndrome. Nephrol Dial Transplant. 2009; 24: 1851-1857Taranta А., Gianviti А. Genetic risk factors in typical haemolytic uraemic syndrome. Nephrol Dial Transplant. 2009; 24: 1851-1857Calderon Toledo C., Rogers T.J., Svensson M. et al. Shiga toxin-mediated disease in MyD88-deficient mice infected with Escherichia coli O157:H7. Am J Pathol. 2008; 173(5):1428-1439Calderon Toledo C., Rogers T.J., Svensson M. et al. Shiga toxin-mediated disease in MyD88-deficient mice infected with Escherichia coli O157:H7. Am J Pathol. 2008; 173(5):1428-1439Эмирова Х.М., Попа А.В., Козловская Н.Л. и соавт. Наследственная тромбофилия как фактор риска тяжелого течения гемолитико-уремического синдрома у детей. Педиатрия 2014 (2): 11-19Эмирова Х.М., Попа А.В., Козловская Н.Л. и соавт. Наследственная тромбофилия как фактор риска тяжелого течения гемолитико-уремического синдрома у детей. Педиатрия 2014 (2): 11-19Buteau C., Proulx F. Leukocytosis in children with Escherichia coli O157:H7 enteritis developing the hemolytic-uremic syndrome. Pediatr Infect Dis J. 2000; 19(7):642-647Buteau C., Proulx F. Leukocytosis in children with Escherichia coli O157:H7 enteritis developing the hemolytic-uremic syndrome. Pediatr Infect Dis J. 2000; 19(7):642-647Tserenpuntsag B., Chang H-G et al. Hemolytic Uremic Syndrome Risk and Escherichia coli O157:H7. Emerging Infectious Diseases. 2005; 11 (12): 1955-1957Tserenpuntsag B., Chang H-G et al. Hemolytic Uremic Syndrome Risk and Escherichia coli O157:H7. Emerging Infectious Diseases. 2005; 11 (12): 1955-1957Wong C.S., Mooney J.C. et al. Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis. Clin Infect Dis. 2012; 55(1):33-41Wong C.S., Mooney J.C. et al. Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis. Clin Infect Dis. 2012; 55(1):33-41Nestoridi E., Kushak R.I., Duguerre D. et al.Up-regulation of tissue factor activity on human proximal tubular epithelial cells in response to Shiga toxin. Kidney Int. 2005; 67(6):2254-2266Nestoridi E., Kushak R.I., Duguerre D. et al.Up-regulation of tissue factor activity on human proximal tubular epithelial cells in response to Shiga toxin. Kidney Int. 2005; 67(6):2254-2266Noris M., Remuzzi G. Hemolytic uremic syndrome. J Am Soc Nephrol 2005; 16:1035-1050Noris M., Remuzzi G. Hemolytic uremic syndrome. J Am Soc Nephrol 2005; 16:1035-1050Rahman R.C., Cobenas C.J., Drut R. et al. Hemorragic colitis in postdiarrheal hemolytic uremic syndrome: Retrospective analysis of 54 children. Pediat Nephrol 2012; 27:229-233Rahman R.C., Cobenas C.J., Drut R. et al. Hemorragic colitis in postdiarrheal hemolytic uremic syndrome: Retrospective analysis of 54 children. Pediat Nephrol 2012; 27:229-233Ake J.A., Jelacic S., Ciol MAWatkins S.L. et al. Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion. Pediatrics. 2005; 115:673-680Ake J.A., Jelacic S., Ciol MAWatkins S.L. et al. Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion. Pediatrics. 2005; 115:673-680Balestracci A., Martin S.M., Toledo I. et al. Dehydration at admission increased the need for dialysis in hemolytic uremic syndrome children. Pediatr Nephrol 2012; 27:1407Balestracci A., Martin S.M., Toledo I. et al. Dehydration at admission increased the need for dialysis in hemolytic uremic syndrome children. Pediatr Nephrol 2012; 27:1407Зверев Д.В., Теблоева Л.Т. Почечная недостаточность. В: Таболина В.А., Бельмер С.В., Османов И.М., ред. Нефрология детского возраста. Медпрактика., М., 2005; 539-580Зверев Д.В., Теблоева Л.Т. Почечная недостаточность. В: Таболина В.А., Бельмер С.В., Османов И.М., ред. Нефрология детского возраста. Медпрактика., М., 2005; 539-580Зверев Д.В., Макулова А.И., Лифшиц В.И. и др. Выбор метода заместительной почечной терапии при острой почечной недостаточности у детей. Педиатрия 2007; 86(6):45-51Зверев Д.В., Макулова А.И., Лифшиц В.И. и др. Выбор метода заместительной почечной терапии при острой почечной недостаточности у детей. Педиатрия 2007; 86(6):45-51Лойманн Э., Цыгин А.Н., Саркисян А.А. Детская нефрология: практическое руководство. ЛигТерра., М., 2010; 184-193Лойманн Э., Цыгин А.Н., Саркисян А.А. Детская нефрология: практическое руководство. ЛигТерра., М., 2010; 184-193Nathanson S., Kwon Th. Acute Neurological Involvement in Diarrhea-Associated Hemolytic Uremic Syndrome. Clin J Am Soc Nephrol. 2010; 5:1218-1228Nathanson S., Kwon Th. Acute Neurological Involvement in Diarrhea-Associated Hemolytic Uremic Syndrome. Clin J Am Soc Nephrol. 2010; 5:1218-1228Paton A.W., Paton J.C. Enterobacter cloacae producing a Shiga-like toxin II-related cytotoxin associated with a case of hemolytic-uremic syndrome. J Clin Microbiol. 1996;34(2):463-465Paton A.W., Paton J.C. Enterobacter cloacae producing a Shiga-like toxin II-related cytotoxin associated with a case of hemolytic-uremic syndrome. J Clin Microbiol. 1996;34(2):463-465Garg A.X., Suri R.S., Barrowman N. et al. Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review., meta-analysis., and meta-regression. JAMA. 2003;290: 1360-1370Garg A.X., Suri R.S., Barrowman N. et al. Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review., meta-analysis., and meta-regression. JAMA. 2003;290: 1360-1370Askiti V., Hendrickson K., Fish A.J. et al. Troponin I levels in a hemolytic uremic syndrome patient with severe cardiac failure. Pediatr Nephrol 2004; 19:345Askiti V., Hendrickson K., Fish A.J. et al. Troponin I levels in a hemolytic uremic syndrome patient with severe cardiac failure. Pediatr Nephrol 2004; 19:345de Buys Roessingh A.S., de Lagausie P., Baudoin V. et al. Gastrointestinal complications of post-diarrheal hemolytic uremic syndrome. Eur J Pediatr Surg 2007; 17:328de Buys Roessingh A.S., de Lagausie P., Baudoin V. et al. Gastrointestinal complications of post-diarrheal hemolytic uremic syndrome. Eur J Pediatr Surg 2007; 17:328Suri R.S., Mahon J.L., Clark W.F. et al. Relationship between Esherichia coli O157:H7 and diabetes mellitus. Kidney Int Suppl. 2009. 112:44-46Suri R.S., Mahon J.L., Clark W.F. et al. Relationship between Esherichia coli O157:H7 and diabetes mellitus. Kidney Int Suppl. 2009. 112:44-46Kaplan B.S., Meyers K.E., Schulman S.L. The pathogenesis and treatment of hemolytic uremic syndrome. J Am Soc Nephrol. 1998; 9:1126-1133Kaplan B.S., Meyers K.E., Schulman S.L. The pathogenesis and treatment of hemolytic uremic syndrome. J Am Soc Nephrol. 1998; 9:1126-1133Hermos C.R., Janineh M. Shiga Toxin-Producing Escherichia coli in Children: Diagnosis and Clinical Manifestations of O157:H7 and Non-O157:H7 Infection. Journal of clinical microbiology. 2011. 49(3):955-959Hermos C.R., Janineh M. Shiga Toxin-Producing Escherichia coli in Children: Diagnosis and Clinical Manifestations of O157:H7 and Non-O157:H7 Infection. Journal of clinical microbiology. 2011. 49(3):955-959Romina J. Ferna'ndez-Brando., Leticia V. Bentancor et al. Antibody Response to Shiga Toxins in Argentinean Children with Enteropathic Hemolytic Uremic Syndrome at Acute and Long-Term Follow-Up Periods. PLoS ONE. 2011; 6., 4. - e19136Romina J. Ferna'ndez-Brando., Leticia V. Bentancor et al. Antibody Response to Shiga Toxins in Argentinean Children with Enteropathic Hemolytic Uremic Syndrome at Acute and Long-Term Follow-Up Periods. PLoS ONE. 2011; 6., 4. - e19136Bielaszewska M., Dobrindt U., Gärtner J. et al. Aspects of genome plasticity in pathogenic Escherichia coli. Int J Med Microbiol 2007;297:625-39Bielaszewska M., Dobrindt U., Gärtner J. et al. Aspects of genome plasticity in pathogenic Escherichia coli. Int J Med Microbiol 2007;297:625-39Hickey C.A., Beattie T.J., Cowieson J. et al. Early volume expansion during diarrhea and relative nephroprotection during subsequent hemolytic uremic syndrome. Arch Pediatr Adolesc Med 2011; 165:884Hickey C.A., Beattie T.J., Cowieson J. et al. Early volume expansion during diarrhea and relative nephroprotection during subsequent hemolytic uremic syndrome. Arch Pediatr Adolesc Med 2011; 165:884Niaudet P. Treatment and prognosis of Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome (HUS) in children. Up to Date., 2015Niaudet P. Treatment and prognosis of Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome (HUS) in children. Up to Date., 2015Nitschke M., Sayk F., Härtel C et al. Association between azithromycin therapy and duration of bacterial shedding among patients with Shiga toxin-producing enteroaggregative Escherichia coli O104:H4. JAMA 2012; 307:1046Nitschke M., Sayk F., Härtel C et al. Association between azithromycin therapy and duration of bacterial shedding among patients with Shiga toxin-producing enteroaggregative Escherichia coli O104:H4. JAMA 2012; 307:1046Bell B.P., Griffin P.M., Lozano P. et al. Predictors of hemolytic uremic syndrome in children during a large outbreak of Escherichia coli O157:H7 infections. Pediatrics 1997; 100:E12Bell B.P., Griffin P.M., Lozano P. et al. Predictors of hemolytic uremic syndrome in children during a large outbreak of Escherichia coli O157:H7 infections. Pediatrics 1997; 100:E12Siegler R., Oakes R. Hemolytic uremic syndrome., pathogenesis., treatment., and outcome. Curr Opin Paediatr., 2005; 17:200-204Siegler R., Oakes R. Hemolytic uremic syndrome., pathogenesis., treatment., and outcome. Curr Opin Paediatr., 2005; 17:200-204Loirat C., Sonsino E., Hinglais N. et al. Treatment of the childhood haemolytic uraemic syndrome with plasma. A multicentre randomized controlled trial. The French Society of Paediatric Nephrology. Pediatr Nephrol 1988; 2:279Loirat C., Sonsino E., Hinglais N. et al. Treatment of the childhood haemolytic uraemic syndrome with plasma. A multicentre randomized controlled trial. The French Society of Paediatric Nephrology. Pediatr Nephrol 1988; 2:279Rizzoni G., Claris-Appiani A., Edefonti A. et al. Plasma infusion for hemolytic-uremic syndrome in children: results of a multicenter controlled trial. J Pediatr 1988; 112:284Rizzoni G., Claris-Appiani A., Edefonti A. et al. Plasma infusion for hemolytic-uremic syndrome in children: results of a multicenter controlled trial. J Pediatr 1988; 112:284Slavicek J., Puretic Z., Novak M. et al. The role of plasma exchange in the treatment of severe forms of hemolytic-uremic syndrome in childhood. Artif Organs 1995; 19:506Slavicek J., Puretic Z., Novak M. et al. The role of plasma exchange in the treatment of severe forms of hemolytic-uremic syndrome in childhood. Artif Organs 1995; 19:506Poolpol K., Orth-Höller D et al. Interaction of Shiga toxin 2 with complement regulators of the factor H protein family. Mol Immunol. 2014 Mar;58(1):77-84Poolpol K., Orth-Höller D et al. Interaction of Shiga toxin 2 with complement regulators of the factor H protein family. Mol Immunol. 2014 Mar;58(1):77-84Delmas Y., Vendrely B., Clouzeau B. et al. Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab. Nephrol Dial Transplant 2014; 29:565Delmas Y., Vendrely B., Clouzeau B. et al. Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab. Nephrol Dial Transplant 2014; 29:565Kemper M.J. Outbreak of hemolytic uremic syndrome caused by E. coli O104:H4 in Germany: a pediatric perspective. Pediatr Nephrol 2012; 27:161Kemper M.J. Outbreak of hemolytic uremic syndrome caused by E. coli O104:H4 in Germany: a pediatric perspective. Pediatr Nephrol 2012; 27:161Menne J., Nitschke M., Stingele R. et al. Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ 2012; 345:e4565Menne J., Nitschke M., Stingele R. et al. Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ 2012; 345:e4565Pape L., Hartmann H., Bange F.C. et al. Eculizumab in Typical Hemolytic Uremic Syndrome (HUS) With Neurological Involvement. Medicine (Baltimore) 2015; 94:e1000Pape L., Hartmann H., Bange F.C. et al. Eculizumab in Typical Hemolytic Uremic Syndrome (HUS) With Neurological Involvement. Medicine (Baltimore) 2015; 94:e1000McNeilly T.N., Mitchell M.C. et al. Immunization of cattle with a combination of purified intimin-531., EspA and Tir significantly reduces shedding of Escherichia coli O157:H7 following oral challenge. Vaccine. 2010;28:1422-1428McNeilly T.N., Mitchell M.C. et al. Immunization of cattle with a combination of purified intimin-531., EspA and Tir significantly reduces shedding of Escherichia coli O157:H7 following oral challenge. Vaccine. 2010;28:1422-1428Ritchie J.M.,Greenwich J.L. et al. An Escherichiacoli O157-specificengi- neeredpyocinpreventsandamelio- ratesinfectionby E. coli O157., H7 in ananimalmodelofdiarrhealdis- ease. Antimicrob. AgentsChemother. 2011; 55., 5469-5474Ritchie J.M.,Greenwich J.L. et al. An Escherichiacoli O157-specificengi- neeredpyocinpreventsandamelio- ratesinfectionby E. coli O157., H7 in ananimalmodelofdiarrhealdis- ease. Antimicrob. AgentsChemother. 2011; 55., 5469-5474Trachtman H., Cnaan A., Christen E. et al. Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: a randomized controlled trial. JAMA 2003; 290:1337Trachtman H., Cnaan A., Christen E. et al. Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: a randomized controlled trial. JAMA 2003; 290:1337Lopez E.L., Contrini M.M. et al. Safety and pharmacokinetics of urtoxazumab., a humanized monoclonal antibody., against Shiga-like toxin 2 in healthy adults and in pediatric patients infected with Shiga-like toxin-producing Escherichia coli. Antimicrob Agents Chemother. 2010;54:239-243Lopez E.L., Contrini M.M. et al. Safety and pharmacokinetics of urtoxazumab., a humanized monoclonal antibody., against Shiga-like toxin 2 in healthy adults and in pediatric patients infected with Shiga-like toxin-producing Escherichia coli. Antimicrob Agents Chemother. 2010;54:239-243Smith M.J., Teel L.D. et al. Development of a hybrid Shiga holotoxoid vaccine to elicit heterologous protection against Shiga toxins types 1 and 2. Vaccine. 2006b;24:4122-4129Smith M.J., Teel L.D. et al. Development of a hybrid Shiga holotoxoid vaccine to elicit heterologous protection against Shiga toxins types 1 and 2. Vaccine. 2006b;24:4122-4129Wahome P.G., Bai Y. et al. Identification of small-molecule inhibitors of ricin and shiga toxin using a cell-based high-throughput screen.Toxicon. 2010;56:526-534Wahome P.G., Bai Y. et al. Identification of small-molecule inhibitors of ricin and shiga toxin using a cell-based high-throughput screen.Toxicon. 2010;56:526-534Watanabe-Takahashi M., Sato T. et al. An orally applicable Shiga toxin neutralizer functions in the intestine to inhibit the intracellular transport of the toxin. Infect Immun. 2010;78:177-183Watanabe-Takahashi M., Sato T. et al. An orally applicable Shiga toxin neutralizer functions in the intestine to inhibit the intracellular transport of the toxin. Infect Immun. 2010;78:177-183Sandvig K., Bergan J. et al. Endocytosis and retrograde transport of Shiga toxin. Toxicon: 2009Sandvig K., Bergan J. et al. Endocytosis and retrograde transport of Shiga toxin. Toxicon: 2009Jandhyala D.M., Ahluwalia A. et al. a MAP3Kinase that transduces Shiga toxin- and ricin-induced proinflammatory cytokine expression. Cell Microbiol. 2008;10:1468-1477Jandhyala D.M., Ahluwalia A. et al. a MAP3Kinase that transduces Shiga toxin- and ricin-induced proinflammatory cytokine expression. Cell Microbiol. 2008;10:1468-1477Ohara S., Kawasaki Y. et al. Role of vascular endothelial growth factor and angiopoietin 1 in renal injury in hemolytic uremic syndrome. Am J Nephrol. 2012;36(6):516-523Ohara S., Kawasaki Y. et al. Role of vascular endothelial growth factor and angiopoietin 1 in renal injury in hemolytic uremic syndrome. Am J Nephrol. 2012;36(6):516-523Obrig T.G., Karpman D. Shiga Toxin Pathogenesis: Kidney Complications and Renal Failure. Curr Top Microbiol Immunol. 2012 ; 357:105-136Obrig T.G., Karpman D. Shiga Toxin Pathogenesis: Kidney Complications and Renal Failure. Curr Top Microbiol Immunol. 2012 ; 357:105-136Spinale J.M., Ruebner R.L. et al. Update on Streptococcus pneumoniae associated hemolytic uremic syndrome. Curr Opin Pediatr. 2013;25(2):203-208Spinale J.M., Ruebner R.L. et al. Update on Streptococcus pneumoniae associated hemolytic uremic syndrome. Curr Opin Pediatr. 2013;25(2):203-208Loos S., Ahlenstiel Th., Krany B., Markus J.K. An outbreak of shiga toxin-producing E.coli 0104:H4 HUS in Germany: presentation and short term outcome in children. Clinical Infectious Disease. 2012; 55(6):753-759Loos S., Ahlenstiel Th., Krany B., Markus J.K. An outbreak of shiga toxin-producing E.coli 0104:H4 HUS in Germany: presentation and short term outcome in children. Clinical Infectious Disease. 2012; 55(6):753-759Magnus T., Röther J., Simova O. et al. Neurological syndrome in adults during the 2011 northern German E. coli serotype O104:H4 outbreak. Brain. 2012;135(6):1850-1859Magnus T., Röther J., Simova O. et al. Neurological syndrome in adults during the 2011 northern German E. coli serotype O104:H4 outbreak. Brain. 2012;135(6):1850-1859Tufro A., Arrizurieta E.E., Repeto H. Renal functional reserve in children with a previous episode of hemolytic uremic syndrome. Pediatr Nephrol 1991; 5:184-188Tufro A., Arrizurieta E.E., Repeto H. Renal functional reserve in children with a previous episode of hemolytic uremic syndrome. Pediatr Nephrol 1991; 5:184-188Caletti M.G., Missoni M., Vezzani C. Effect of diet., enalapril., or losartan in post-diarrheal hemolytic uremic syndrome nephropathy. Pediatr Nephrol 2001. 26:1247-1254Caletti M.G., Missoni M., Vezzani C. Effect of diet., enalapril., or losartan in post-diarrheal hemolytic uremic syndrome nephropathy. Pediatr Nephrol 2001. 26:1247-1254De Petris L., Gianviti A., Giordano U. et al. Blood pressure in the long-term follow-up of children with haemolytic uraemic syndrome. Pediatr Nephrol 2004; 19:1241-1244De Petris L., Gianviti A., Giordano U. et al. Blood pressure in the long-term follow-up of children with haemolytic uraemic syndrome. Pediatr Nephrol 2004; 19:1241-1244Van Dyck M., Proesmans W. Renoprotection by ACE ingibitors after severe hemolytic uremic syndrome. Pediatr Nephrol 2003; 18: 688-690Van Dyck M., Proesmans W. Renoprotection by ACE ingibitors after severe hemolytic uremic syndrome. Pediatr Nephrol 2003; 18: 688-690Ferraris J.R., Ramirez J.A., Ruiz S. et al. Shiga toxin-associated hemolytic uremic syndrome: Absence of recurrence after renal transplantation. Pediatr Nephrol 2002. 17: 809-814Ferraris J.R., Ramirez J.A., Ruiz S. et al. Shiga toxin-associated hemolytic uremic syndrome: Absence of recurrence after renal transplantation. Pediatr Nephrol 2002. 17: 809-814

The authors declare that there are no conflicts of interest present.